Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document concludes that treating skin conditions should include psychological care and a multidisciplinary approach is essential for effective management.

This review discusses OCD spectrum disorders with dermatological symptoms, emphasizing their clinical features, neurobiology, and treatment options, while noting the need for more controlled studies.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

This review discusses the potential for mood stabilizers, antidepressants, and some antipsychotic and antianxiety drugs to induce alopecia and reports no clinical results.

In this study, the researchers reviewed psychiatric drugs approved between 2002 and 2022 to analyze trends in drug repurposing, finding an increased application of repurposing methods, especially through fixed-dose combinations, and highlighting technologies like SmartCube® to predict efficacy from animal models.

This paper reviews the growing use of psychotropic drugs in dermatology due to the link between mental states and skin conditions but does not present new clinical findings.

This article argues that psychoactive drugs are often beneficial in treating dermatological conditions with psychiatric or psycho-emotional components but does not present new clinical evidence.

This review analyzes how the pharmaceutical industry's emphasis on lifestyle drugs and marketing practices leads to the integration of pharmaceuticals into everyday life, with a domestic focus and view of drugs as quick solutions.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.

In this study of transgender and gender-diverse adults, the researchers observed that one-third of those on psychotropic medications within two years of starting hormone therapy experienced psychotropic polypharmacy, with a significantly higher likelihood of potential drug-hormone interactions in this group.

This article reviews the historical development of pharmacology up to the mid-20th century and outlines its transition from a support role in therapeutics to a distinct scientific discipline, but reports no new findings.

This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.

This review provides practical guidelines for managing psychodermatologic disorders and concludes that psychopharmacologic agents offer a useful option for treatment, considering the underlying psychopathologic condition.

This article discusses lifestyle drugs, their subjective value, and the challenges in determining who should pay for them, highlighting the need for consensus on priorities and strategies.

This paper discusses the use of lifestyle drugs by individuals without medical conditions to enhance appearance, highlighting that such usage may worsen emotional disorders and suggests these should be treated with psychotherapy or psychopharmacotherapy.

The conclusion is that combining social and cultural factors with pharmaceutical research could improve our understanding of how drugs work.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

This review discusses the relationship between stress and skin disorders, highlighting psychodermatoses and recommending mind-body techniques and collaborative care involving dermatology, psychiatry, and psychology, without reporting new clinical results.

Crash diets can cause temporary hair loss, and professional medical advice can prevent serious health issues.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This review discusses the complex relationship between psychotropic medications and the skin, focusing on cutaneous side effects, dermatologic uses, and psychiatric disorders with skin manifestations, but reports no new findings.

This article discusses common dermatologic side effects of psychopharmacologic agents such as eruptions, urticaria, and photosensitivity, but it reports no new research findings.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

This article discusses historical serendipitous discoveries in science and medicine but provides no new research findings.

This review examines psychosomatic hair diseases, discussing their classification, implications, and the need for tailored psychosomatic therapy, without reporting new clinical results.

This case report highlights an interest in exploring the relationship between serum levels of sodium valproate and hair loss, though no case reports currently establish this link.

This case report describes the first known instance of hair loss linked to agomelatine, which resolved after the drug was discontinued.

This article discusses the increasing use of lifestyle drugs by healthy individuals to alter appearance or slow aging and emphasizes the need for doctors to consider side effects and contraindications, but it reports no new clinical findings.